Ovary Neoplasm

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Ovary Neoplasm trials you may qualify for

100

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 60 trials

RecruitingPhase 1/2

NCT06188520

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com…

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, a…

United States, Australia564 participantsStarted 2023-12-05

Treatment: AZD8421, Camizestrant

RecruitingPhase 1

NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe fo…

United States1,006 participantsStarted 2020-06-08

Treatment: sigvotatug vedotin, pembrolizumab

RecruitingNot Applicable

NCT01950572

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothel…

United States1,000 participantsStarted 2013-09-09

RecruitingPhase 3

NCT07544030

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol…

Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.

China60 participantsStarted 2025-11-10

Treatment: PIPAC

RecruitingPhase 1

NCT06257264

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmaco…

United States258 participantsStarted 2024-03-11

Treatment: BG-68501, Fulvestrant

RecruitingPhase 1

NCT05950464

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer tha…

United States65 participantsStarted 2023-12-18

Treatment: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure

All recent trials (100 shown)

Active — Not RecruitingNot Applicable

NCT05185388

Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017

This study is a population-based, patient-level analysis of colon and ovarian cancer diagnoses in England over a 2-year period using a dataset created by linkin…

United Kingdom45,831 participantsStarted 2021-10-25

Active — Not RecruitingPhase 1/2

NCT04152499

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Ava…

United States1,410 participantsStarted 2020-02-28

Treatment: SKB264

Ovary Neoplasm

Trial phase breakdown

Trial status

Actively recruiting — 60 trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com…

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol…

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

All recent trials (100 shown)

Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Trial phase breakdown

Trial status

Actively recruiting — 60 trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Com…

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol…

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

All recent trials (100 shown)

Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vac…

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Can…

Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased G…

Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic…

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Family History App in Personalized Medicine

PF-07104091 as a Single Agent and in Combination Therapy

Rapid Autopsy and Procurement of Cancer Tissue

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Lip…

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Distress, Anxiety and Psychosexual Health in BOT

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Plati…